Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

European Journal of Cancer

Volumn 60, Issue , 2016, Pages 210-225

  Zimmer, Lisa ^a   Goldinger, Simone M ^b   Hofmann, Lars ^c   Loquai, Carmen ^d   Ugurel, Selma ^a   Thomas, Ioannis ^e   Schmidgen, Maria I ^d   Gutzmer, Ralf ^f   Utikal, Jochen S ^g,h   Göppner, Daniela ⁱ   Hassel, Jessica C ^j   Meier, Friedegund ^k   Tietze, Julia K ^l   Forschner, Andrea ^e   Weishaupt, Carsten ^m   Leverkus, Martin ⁿ   Wahl, Renate ⁿ   Dietrich, Ursula ^k   Garbe, Claus ^e   Kirchberger, Michael C ^c   Eigentler, Thomas ^e   Berking, Carola ^l   Gesierich, Anja ^o   Krackhardt, Angela M ^p   Schadendorf, Dirk ^a   Schuler, Gerold ^c   Dummer, Reinhard ^b   Heinzerling, Lucie M ^c   more..

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^o UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Adverse event; Anti PD 1; Checkpoint inhibitors; Immune related; Nivolumab; Pembrolizumab; Side effect; Tolerability; Toxicity

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CARBOPLATIN; CORTICOSTEROID; CREATINE KINASE; DABRAFENIB; DACARBAZINE; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; IPILIMUMAB; LA ANTIBODY; LEVETIRACETAM; LORAZEPAM; MAGNESIUM; METHYLPREDNISOLONE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; PREGABALIN; PROGRAMMED DEATH 1 RECEPTOR; PYRIDOSTIGMINE; RO ANTIBODY; SMOOTH MUSCLE ANTIBODY; SULTAMICILLIN; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; ADVERSE DRUG REACTION; AGED; ANEMIA; ANGINA PECTORIS; ANTIBIOTIC THERAPY; APHASIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BLURRED VISION; BRADYKINESIA; BRAIN METASTASIS; BRONCHITIS; CARDIOVASCULAR DISEASE; CONJUNCTIVITIS; CORONARY ANGIOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; COXITIS; CYSTITIS; DEMYELINATION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EYE DISEASE; EYE MOVEMENT DISORDER; FATIGUE; FEMALE; GASTRITIS; GERMANY; GINGIVITIS; GUILLAIN BARRE SYNDROME; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HEMOPTYSIS; HIP PAIN; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IRITIS; LARYNX EDEMA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG FIBROSIS; LUNG METASTASIS; LUNG SARCOIDOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NEUROLOGIC DISEASE; NEUTROPENIA; OTITIS; OXYGEN SATURATION; PARALYSIS; PARESIS; PARESTHESIA; PARKINSONISM; PHARYNGITIS; PLASMAPHERESIS; PNEUMONIA; POLYNEUROPATHY; POLYRADICULITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RADICULITIS; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; SEIZURE; SHOULDER ARTHRITIS; SIDE EFFECT; SINUS TACHYCARDIA; SINUSITIS; SOFT TISSUE METASTASIS; SWITZERLAND; SYNOVITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC THERAPY; TAKOTSUBO CARDIOMYOPATHY; UVEITIS; VOICE CHANGE; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMICALLY INDUCED; CLINICAL TRIAL; HEART DISEASE; MELANOMA; SKIN NEOPLASMS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; EYE DISEASES; FEMALE; HEART DISEASES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUSCULOSKELETAL DISEASES; NERVOUS SYSTEM DISEASES; PROGRAMMED CELL DEATH 1 RECEPTOR; RESPIRATORY TRACT DISEASES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84964389238     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.02.024     Document Type: Article

References (38)

1. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol 19 7 2007 Jul 813 824 [Internet] [cited 2015 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17606980
2. A. Ribas Tumor immunotherapy directed at PD-1 N Engl J Med 366 26 2012 Jun 28 2517 2519 [Internet] [cited 2015 Aug 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22658126
3. S.J. O'Day, M. Maio, V. Chiarion-Sileni, T.F. Gajewski, H. Pehamberger, I.N. Bondarenko, and et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol 21 8 2010 Aug 1712 1717 [Internet] [cited 2015 Sep 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20147741
4. J.S. Weber, S.P. D'Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 16 4 2015 Apr 375 384 [Internet] [cited 2015 Jun 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25795410
5. C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 26 2015 Apr 19 150419053123009 [Internet] [cited 2015 Apr 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891173
6. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 1 2015 Jul 2 23 34 [Internet] [cited 2015 Jun 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26027431
7. H. Läubli, C. Balmelli, M. Bossard, O. Pfister, K. Glatz, and A. Zippelius Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma J Immunother Cancer 3 1 2015 Apr 21 11 [Internet] [cited 2016 Jan 12]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4404586&tool=pmcentrez&rendertype=abstract
8. L. Min, and F.S. Hodi Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis Cancer Immunol Res 2 1 2014 Jan 15 18 [Internet] [cited 2016 Jan 10]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4006358&tool=pmcentrez&rendertype=abstract
9. M. Yoshioka, N. Kambe, Y. Yamamoto, K. Suehiro, and H. Matsue Case of respiratory discomfort due to myositis after administration of nivolumab J Dermatol 42 10 2015 Dec 24 1008 1009 [Internet] [cited 2015 Sep 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26104017
10. B. Liao, S. Shroff, C. Kamiya-Matsuoka, and S. Tummala Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma Neuro Oncol 16 4 2014 Apr 589 593 [Internet] [cited 2015 Oct 13]. Available from: http://neuro-oncology.oxfordjournals.org/cgi/doi/10.1093/neuonc/nou001
11. C.J. Voskens, S.M. Goldinger, C. Loquai, C. Robert, K.C. Kaehler, C. Berking, and et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network PLoS One 8 1 2013 Jan e53745 [Internet] [cited 2015 Sep 9]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3544906&tool=pmcentrez&rendertype=abstract
12. S. Wilgenhof, and B. Neyns Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient Ann Oncol 22 4 2011 Apr 991 993 [Internet] [cited 2015 Sep 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21357649
13. I. Bot, C.U. Blank, W. Boogerd, and D. Brandsma Neurological immune-related adverse events of ipilimumab Pract Neurol 13 4 2013 Aug 278 280 [Internet] [cited 2015 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23487828
14. S. Bhatia, B.R. Huber, M.P. Upton, and J.A. Thompson Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report J Immunother 32 2 2009 Feb 203 205 [Internet] [cited 2015 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19238020
15. Keytruda: Fachinformation, http://www.msd.de/fileadmin/files/fachinformationen/keytruda.pdf [accessed 19.01.16].
16. Opdivo: Zusammenfassung der Merkmale des Arzneimittels, http://ec.europa.eu/health/documents/community-register/2015/20150619132099/anx-132099-de.pdf [accessed 19.01.16].
17. J. Brahmer, K.L. Reckamp, P. Baas, L. Crinò, W.E.E. Eberhardt, E. Poddubskaya, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 2 2015 Jul 9 123 135 [Internet] [cited 2015 Jun 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26028407
18. J.S. Weber, R.R. Kudchadkar, B. Yu, D. Gallenstein, C.E. Horak, H.D. Inzunza, and et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J Clin Oncol 31 34 2013 Dec 1 4311 4318 [Internet] [cited 2015 Mar 24]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3837092&tool=pmcentrez&rendertype=abstract
19. J.J. Mandel, A. Olar, K.D. Aldape, and I.W. Tremont-Lukats Lambrolizumab induced central nervous system (CNS) toxicity J Neurol Sci 344 0 2014 Sep 15 229 231 [Internet] [cited 2016 Jan 19]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4157634&tool=pmcentrez&rendertype=abstract
20. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.-J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 Jun 28 2455 2465 [Internet] [cited 2015 Feb 13]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3563263&tool=pmcentrez&rendertype=abstract
21. Keytruda: highlights of prescribing information, http://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf [accessed 12.10.15].
22. Opdivo: highlights of prescribing information, http://packageinserts.bms.com/pi/pi-opdivo.pdf [accessed 08.10.15].
23. C. Maurice, R. Schneider, T.-R. Kiehl, P. Bavi, M.H.A. Roehrl, W.P. Mason, and et al. Subacute CNS demyelination after treatment with nivolumab for melanoma Cancer Immunol Res 3 12 2015 Dec 1299 1302 [Internet] [cited 2015 Nov 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26419960
24. M.A. Postow Managing immune checkpoint-blocking antibody side effects Am Soc Clin Oncol Educ Book 35 2015 Jan 76 83 [Internet] [cited 2015 Jun 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993145
25. W.V. Vogel, A. Guislain, P. Kvistborg, T.N.M. Schumacher, J.B.A.G. Haanen, and C.U. Blank Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission J Clin Oncol 30 2 2012 Jan 10 e7 e10 [Internet] [cited 2015 Sep 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22124094
26. A. Eckert, A. Schoeffler, S. Dalle, A. Phan, L. Kiakouama, and L. Thomas Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient Dermatology 218 1 2009 Jan 69 70 [Internet] [cited 2015 Sep 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18832811
27. S. Wilgenhof, V. Morlion, A.C. Seghers, S. Du Four, E. Vanderlinden, S. Hanon, and et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor Anticancer Res 32 4 2012 Apr 1355 1359 [Internet] [cited 2015 Sep 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22493370
28. I.Z. Barjaktarevic, N. Qadir, A. Suri, J.T. Santamauro, and D. Stover Organizing pneumonia as a side effect of ipilimumab treatment of melanoma Chest 143 3 2013 Mar 858 861 [Internet] [cited 2015 Sep 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23460165
29. G. Berthod, R. Lazor, I. Letovanec, E. Romano, L. Noirez, J. Mazza Stalder, and et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab J Clin Oncol 30 17 2012 Jun 10 e156 e159 [Internet] [cited 2015 Sep 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22547608
30. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 Jun 28 2443 2454 [Internet] [cited 2014 Aug 12]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3544539&tool=pmcentrez&rendertype=abstract
31. N.A. Rizvi, J. Mazières, D. Planchard, T.E. Stinchcombe, G.K. Dy, S.J. Antonia, and et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 3 2015 Mar 257 265 [Internet] [cited 2015 Feb 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25704439
32. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 10 2014 Apr 1 1020 1030 [Internet] [cited 2015 Mar 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24590637
33. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 21 2015 May 21 2018 2028 [Internet] [cited 2015 Apr 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891174
34. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 19 2010 Jul 1 3167 3175 [Internet] [cited 2015 May 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20516446
35. M. Nishino, L.M. Sholl, H. Hatabu, N.H. Ramaiya, and F.S. Hodi Anti-PD-1-related pneumonitis during cancer immunotherapy N Engl J Med 373 3 2015 Jul 16 288 290 [Internet] [cited 2015 Jul 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26176400
36. Yervoy: summary of product characteristics, http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002213/WC500109299.pdf [accessed 15.10.15].
37. G. de Velasco, B. Bermas, and T.K. Choueiri Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment Arthritis Rheumatol (Hoboken, NJ) 68 2 2016 Feb 556 557 [Internet] [cited 2016 Jan 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26314277
38. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.-J. Hwu, R. Kefford, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2 2013 Jul 11 134 144 [Internet] [cited 2015 Sep 14]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4126516&tool=pmcentrez&rendertype=abstract